At Investor Conferences

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px
Document › Details

MorphoSys AG. (1/3/17). "Press Release: MorphoSys to Present at Upcoming Investor Conferences". Planegg.

Region Region San Francisco, CA
  Country United States (USA)
Organisation Organisation MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
Product Product J.P. Morgan 35th Annual Healthcare Conference 2017 San Francisco
Person Person Moroney, Simon E. (MorphoSys 1992–201908 CEO + Founder STEPPED DOWN 9/19)
     


MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conferences:

J.P. Morgan Healthcare Conference
Date: January 12, 2017, 7:30 am PST (4:30 pm CET, 3:30 pm GMT)
Venue: San Francisco, CA, USA
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG,
Anke Linnartz, Head of Corporate Communications & IR

Kepler Cheuvreux German Corporate Conference
Date: January 17, 2017, 4:45 pm CET (10:45 am EST, 3:45 pm GMT)
Venue: Frankfurt, Germany
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG,
Anke Linnartz, Head of Corporate Communications & IR

A PDF version of the presentation will be provided at www.morphosys.com. The link to webcasts will be filed under www.morphosys.com/conference-calls.


About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.


For more information, please contact:

MorphoSys AG

Anke Linnartz
Head of Corporate Communications & IR

Jochen Orlowski
Associate Director Corporate Communications & IR

Alexandra Goller
Senior Manager Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com

   
Record changed: 2017-07-02

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x112px

More documents for MorphoSys (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture [LSBNL] Life-Sciences-Benelux.com – The Business Web Portal 600x86px




» top